Indications for: OPTIRAY 300
Cerebral arteriography. Computed tomography (CT) imaging of the head and body, venography, and intravenous (IV) excretory urography.
Individualize. Cerebral arteriography (carotid or vertebral arteries): 2–12mL; (aortic arch inj [four vessel study]): 20–50mL; both: may repeat as necessary; max 200mL. Peripheral arteriography (aortic-iliac runoff): 60mL (range 20–90mL); (common iliac, femoral): 40mL (range 10–50mL); (subclavian, brachial): 20mL (range 15–30mL); all: max 250mL. Venography: 50–100mL per extremity; max 250mL. CT (head): 50–150mL by infusion; (body): may give as 25–75mL bolus inj or 50–150mL by infusion, or combination of both. IV urography (usual dose): 50–75mL; (high dose): 1.6mL/kg; max 150mL.
OPTIRAY 300 Contraindications:
Risks with inadvertent intrathecal administration. For intra-arterial and intravenous use only.
OPTIRAY 300 Warnings/Precautions:
Inadvertent intrathecal administration; may cause death, convulsions, cerebral hemorrhage, coma, paralysis, arachnoiditis, acute renal failure, cardiac arrest, seizures, rhabdomyolysis, hyperthermia, and brain edema. History of previous reactions to a contrast agent and known allergies (eg, bronchial asthma, drug, or food) and other hypersensitivities; monitor. Should be administered by professional trained in use of radiopaque agents in appropriate facilities with emergency treatment readily available. Monitor for severe cardiovascular reactions. Risk of serious thromboembolic events (eg, MI, stroke) during angiographic procedures. Avoid angiography with homocystinuria. CHF. Dehydration. Diabetes. Advanced vascular disease. Multiple myeloma or other paraproteinemia. Hyperthyroidism. Autonomous thyroid nodule. Thyroid dysfunction (esp. children 0–3yrs); monitor. Pheochromocytoma or catecholamine-secreting paraganglioma: monitor closely. Homozygous sickle cell disease. History of severe cutaneous adverse reactions (SCAR); avoid. Hepatic or renal impairment. Use lowest effective dose. Maintain adequate hydration. Avoid extravasation. Elderly. Pregnancy. Nursing mothers: consider interrupting, pumping, and discarding breast milk for 8hrs after Optiray.
OPTIRAY 300 Classification:
Radiopaque contrast agent.
OPTIRAY 300 Interactions:
Increased risk of metformin-induced lactic acidosis; discontinue metformin at the time of, or prior to, Optiray in high risk patients (see full labeling). May antagonize radioactive iodine for thyroid carcinoma for up to 6–8wks. Defer in patients with hepatic impairment who recently received oral cholecystographic contrast agents. Caution with concomitant diuretics, nephrotoxic agents. Avoid laxatives, diuretics prior to administration. Protein-bound iodine or radioactive iodine uptake study results may not accurately reflect thyroid function for up to 16 days.
Nausea; hypersensitivity reactions, acute kidney injury, cardiovascular reactions, SCAR (eg, SJS/TEN, DRESS). Also in children: fever.
Half-life: 1.5 hours.
Peak urine concentration occurs in the first 2 hours after administration.
Generic Drug Availability:
OPTIRAY 300: Bottles (50mL)—25, 100mL, 150mL, 200mL—12, Syringes (100mL)—20, RFID-Tagged syringes (100mL)—20; OPTIRAY 320: Vials (20mL)—25, Bottles (50mL)—25, 100mL, 150mL, 200mL—12, Syringes (50mL, 75mL, 100mL, 125mL)—20, RFID-Tagged syringes (75mL, 100mL, 125mL)—20; OPTIRAY 350: Bottles (50mL)—25, 100mL, 150mL, 200mL—12, Syringes (50mL, 75mL, 100mL, 125mL)—20, RFID-Tagged syringes (100mL, 125mL)—20